DERIGLIDOLE

Details

Stereochemistry	UNKNOWN
Molecular Formula	C16H21N3
Molecular Weight	255.358
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCC1(CC2=CC=CC3=C2N1CC3)C4=NCCN4

InChI

InChIKey=BADQRNHAZHSOKC-UHFFFAOYSA-N

InChI=1S/C16H21N3/c1-2-7-16(15-17-8-9-18-15)11-13-5-3-4-12-6-10-19(16)14(12)13/h3-5H,2,6-11H2,1H3,(H,17,18)

HIDE SMILES / InChI

Molecular Formula	C16H21N3
Molecular Weight	255.358
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://adisinsight.springer.com/drugs/800000010 | https://www.ncbi.nlm.nih.gov/pubmed/7828647 | Kuhlmann, J., Puls, W. (2013) Oral Antidiabetics, page 661, retrieved from: https://books.google.ru/books?id=QpjsCAAAQBAJ

Deriglidole was reported to inhibit alpha 2-adrenoceptors and ATP-sensitive K+ channels in mouse pancreatic B-cells, and to increase insulin release. The effects of deriglidole are stereoselective on alpha 2-adrenoceptors, but not on ATP-sensitive K+ channels of pancreatic B-cells. Deriglidole had been in phase II clinical trial for the treatment of diabetes mellitus type II in France. However, the study was discontinued.

Approval Year

PubMed

Title	Date	PubMed
Alpha2-adrenoceptor antagonist SL 84.0418 reduces the expression of neocortical spike-and-wave spindling episodes in DBA/2J mice.	2003-02	12551737

Patents

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:19:06 GMT 2025` Edited by `admin` on `Mon Mar 31 18:19:06 GMT 2025`
Record UNII	68EP8R4PMV
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

deriglidole [INN]

Preferred Name

English

DERIGLIDOLE

Official Name

English

(+)-1,2,4,5-TETRAHYDRO-2-(2-IMIDAZOLIN-2-YL)-2-PROPYLPYRROLO(3,2,1-HI)INDOLE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29713